Combining existing drug therapy is essential in develo** new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …

Liposomes, which possess the properties of nano-scale, biofilm similar structure, excellent
biocompatibility, become more and more useful in the drug development as the delivery …

We conducted the Reproducibility Project: Cancer Biology to investigate the replicability of
preclinical research in cancer biology. The initial aim of the project was to repeat 193 …

Abstract Three-dimensional (3D) cell culture technologies, such as organoids, are
physiologically relevant models for basic and clinical applications. Automated microfluidics …

Cancer metastasis is no longer viewed as a linear cascade of events but rather as a series
of concurrent, partially overlap** processes, as successfully metastasizing cells assume …

Abstract P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX)
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …

The current achievements in treating glioblastoma (GBM) patients are not sufficient because
many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem …

Aberrant cell signaling can cause cancer and other diseases and is a focal point of drug
research. A common approach is to infer signaling activity of pathways from gene …

Cancer cell dormancy is a process whereby cells enter reversible cell cycle arrest, termed
quiescence. Quiescence is essential for cancer cells to acquire additional mutations, to …

Hypoxia has been firmly correlated to the drug resistance of solid tumors. Alleviation of
hypoxia by tumor reoxygenation is expected to sensitize the chemotherapy toward solid …